menu
    • menu
    [{"orgOrder":0,"company":"PINOTBIO","sponsor":"Lotte Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"PINOTBIO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PINOTBIO \/ Lotte Biologics","highestDevelopmentStatusID":"4","companyTruncated":"PINOTBIO \/ Lotte Biologics"},{"orgOrder":0,"company":"PINOTBIO","sponsor":"Aptamer Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"FL-118","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PINOTBIO","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PINOTBIO \/ PINOTBIO","highestDevelopmentStatusID":"2","companyTruncated":"PINOTBIO \/ PINOTBIO"},{"orgOrder":0,"company":"PINOTBIO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NTX-101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"PINOTBIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"PINOTBIO \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PINOTBIO \/ Undisclosed"},{"orgOrder":0,"company":"PINOTBIO","sponsor":"PINOTBIO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NTX-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PINOTBIO","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PINOTBIO \/ PINOTBIO","highestDevelopmentStatusID":"7","companyTruncated":"PINOTBIO \/ PINOTBIO"}]

    Find Clinical Drug Pipeline Developments & Deals by PINOTBIO

    Menu

    PINOTBIO

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lotte Biologics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LOTTE BIOLOGICS Announces Investment in PINOT BIO, ADC Platform Development Pioneer

                            Details : The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeti...

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 21, 2023

                            Lead Product(s) : Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lotte Biologics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTX-101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of NTX-101 in Korean Healthy Volunteers

                            Details : NTX-101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 13, 2021

                            Lead Product(s) : NTX-101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FL-118

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Aptamer Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery

                            Details : The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 03, 2021

                            Lead Product(s) : FL-118

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Aptamer Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed

                            PINOTBIO

                            South Korea arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTX-301

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Xennials Therapeutics Australia Pty Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced ...

                            Details : NTX-301 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 20, 2021

                            Lead Product(s) : NTX-301

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Xennials Therapeutics Australia Pty Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth